Skip to main content
. Author manuscript; available in PMC: 2021 Jan 13.
Published in final edited form as: Vaccine. 2020 Dec 1;39(2):412–422. doi: 10.1016/j.vaccine.2020.11.028

Table 5:

Scenario analysis showing the impact of disease burden on the ICER from a Public Healthcare Provider and Societal Perspective in South Africa.

Public Healthcare Provider Perspective ICER (2018 US$) Societal Perspective ICER (2018 US$)
Base case analysis Scenario analysis* Base case analysis Scenario analysis*
Pregnant women 2 010 11 015 Dominant 8 362
PLWHA 1 749 11 361 Dominant 8 012
Persons with UMC 2 618 11 541 Dominant 8 621
Persons aged ≥ 65 years 2 090 15 888 2 034 15 801
Children 6–59 months 7 490 23 620 5 267 21 161

PLWHA: Persons living with HIV/AIDS

UMC: Underlying Medical Conditions

Base case analysis: Incremental Cost-Effectiveness Ratio (ICER) estimated using the broad case definition of influenza-associated illness which includes all respiratory, all circulatory, non-respiratory/non-circulatory influenza-associated illness

Scenario analysis: ICER estimated using the narrower case definition of influenza-associated illness which includes only ILI and SARI, a subset of all respiratory influenza-associated illness

*

Supplementary Figure 5 presents the results of the probabilistic sensitivity analyses for the narrower case definition scenario